<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13455">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137707</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720DCA04T</org_study_id>
    <nct_id>NCT02137707</nct_id>
  </id_info>
  <brief_title>Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya</brief_title>
  <acronym>IGLOO</acronym>
  <official_title>An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether in RRMS patients receiving Gilenya there is a link between
      disease progression and biologic markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The biologic basis that determines disease progression in multiple sclerosis (MS) patients
      remains to be defined.  We propose that a long term study of patients where inflammatory
      activity of the disease is expected to be controlled on treatment, will identify patients
      into cohorts of those whose disease is deemed to be stable with those patients whose disease
      has been deemed to progress.  Once the two groups have been identified, it will then be
      possible to assess whether there are differences in biologic markers between the two groups.
       These markers would then have the potential to be used to monitor disease progression or be
      predictors for patient response to drug treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Determination of disease progression of subjects treated with Gilenya over 5 years</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in the overall EDSS and its subscales will be used to assess disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function in patients treated with Gilenya</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>A battery of cognitive and mood tests including the 5 item Rao's Brief Repeatable Battery of Neuropsychological Tests will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biologic measures in patients treated with Gilenya</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Conventional magnetic resonance (MR) sequences will be acquired to assess changes in number of lesions, normalized brain volume, grey matter and myelin content.
Blood will be collected over the course of the study to assess changes in blood biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Gilenya therapy will be assessed</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety parameters include the initial cardiac effects, liver function, infections and migraines/headaches</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Multiple Sclerosis-Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Gilenya treatment</arm_group_label>
    <description>Gilenya oral form once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilenya</intervention_name>
    <description>All patients will receive Gilenya</description>
    <arm_group_label>Gilenya treatment</arm_group_label>
    <other_name>fingolimod</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, peripheral blood mononuclear cells, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsing-remitting multiple sclerosis deemed by their treating physician to
        be a suitable candidate for Gilenya therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Deemed by the subject's treating physician to be a suitable candidate for Gilenya
             therapy in accordance with the Canadian Product Monograph for Gilenya

          -  has an overall EDSS not above 7.0

          -  is not currently receiving Gilenya

          -  is able to perform adequately for EDSS assessment and cognitive tests

          -  is able to undergo a MRI

          -  is able to provide blood samples

        Exclusion Criteria:

          -  is over 65 years of age and under 18 years of age

          -  has less than 4 weeks of discontinuation with steroid treatment for a relapse.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Antel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amit Bar-Or, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jack Antel, MD</last_name>
    <phone>514-398-5951</phone>
    <email>jack.antel@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amit Bar-Or, MD</last_name>
    <phone>514-398-5132</phone>
    <email>amit.bar-or@mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fabrizio Guiliani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anthony Traboulsee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark Freedman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Lemieux, M.Sc.</last_name>
      <phone>514-398-2667</phone>
      <email>marc.lemieux@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rosanne Seguin, Ph.D.</last_name>
      <phone>514-398-2184</phone>
      <email>rosanne.seguin@mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jack Antel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amit Bar-Or, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Jack Antel</investigator_full_name>
    <investigator_title>Professor, M.D.</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis, Relapsing-Remitting</keyword>
  <keyword>Gilenya</keyword>
  <keyword>Fingolimod</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fingolimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
